| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2008 | Dec, 2007 | Dec, 2006 |
| Sales | 0 | 0 | 144,420 | 55,610 | 128,680 |
| Sales Growth | unch | -100.00% | +159.70% | -56.78% | +14.67% |
| Net Income | -226,790 | -65,320 | -10,440 | -21,270 | -41,090 |
| Net Income Growth | -247.20% | -525.67% | +50.92% | +48.24% | -5.58% |
Adagio Therapeutics Inc (ADGI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Adagio Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. Adagio Therapeutics Inc. is based in WALTHAM, Mass.
Fiscal Year End Date: 12/31